. Aside from radiation oncology, all of the neurooncological subspecialties listed above were represented.
Beyond issues of author representation, radiotherapy is only discussed in the context of efforts to reduce the dose of radiation or to eliminate radiotherapy entirely from the treatment of patients with certain disease characteristics. Even in clinical situations in which attempts to reduce the radiation dose have failed (such as medulloblastoma) 2, 3 , the authors contend that this is a function of and novel systemic therapies are ongoing; these collaborative undertakings might translate into more meaningful improvements in survival outcomes 14 . Current and future studies also aim to tailor the delivery of radiotherapy by molecular profile and couple this with high-precision technologies designed to individualize both target volume and dose 15 . In this sense, the authors of the CRUK position paper 1 are absolutely correct: the neurooncology community must meet the challenges of treating primary brain tumours with robust research efforts across all boundaries: across disciplines; across geographical borders; across the academia-industry divide; and across the bench-to-bedside spectrum of research. Ensuring that all neuro-oncology disciplines, including radiation oncology, are given a voice as we rise to meet these challenges is imperative to engage in truly collaborative research.
an historical "inadequate understanding of medulloblastoma biology"
1 . Without noting the central conclusion of these studies 2, 3 (the importance of adequate irradiation of the neuraxis in patients with medulloblastoma), the authors proceed to discuss why several previous attempts at radiation dose reduction failed and why future efforts will (hypothetically) succeed.
What should already be known to the panel, as well as to members of the broader neuro-oncology community, is that radiotherapy is an integral component of the treatment of brain malignancies. Radiotherapy confers survival advantages to patients with glioblastoma 4,5 , medulloblastoma 2, 3 , germ cell tumours 6,7 , ependymoma 8 and others 9 . This cost-effective and accessible treatment modality has proven efficacy in the adjuvant setting [2] [3] [4] [5] 8 , as well as in the definitive setting 6, 7 , as a first-line treatment [2] [3] [4] [5] [6] [7] [8] or after prior lines of therapy 10 . Neuro-radiation oncology has witnessed a burgeoning of new techniques, technologies and strategies that will better optimize the therapeutic ratio. For example, stereotactic radiosurgery (SRS) is an increasingly widely used non-operative modality and has provided excellent outcomes with mild toxicities for patients with primary or metastatic intracranial neoplasms 11 . Similarly, proton beam therapy (PBT) offers the potential to minimize late-onset toxicities while preserving disease-related outcomes; this promise is increasingly being realized as clinical data on PBT continue to mature 12, 13 . Furthermore, multidisciplinary efforts to find synergies between the effects of radiotherapy 2 , and we agree entirely that radiation oncology has, and will likely continue to have for many years, a critical role in the treatment of patients with primary brain tumours. In particular, we note the helpful references to newer radiotherapy approaches, such as stereotactic radiosurgery and proton beam therapy, that are advancing the treatment of brain tumours. As noted by Ludmir and colleagues 1 , a substantial portion of our Position Paper 2 is given over to the discussion of radiation oncology.
As stated in our manuscript 2 , this narrative was composed following a series of international, multidisciplinary meetings, hosted by Cancer Research UK, which engaged many individuals involved in brain tumour research and treatment. It is important to note that our manuscript is a Position Paper and not a Meeting Report. Thus, rather than synthesising the entirety of the discussions that took place during these meetings, it reports the opinions of those authors listed on the paper. The discussions held by the committee did indeed engage radiation oncologists as well as individuals in other disciplines; however, other commitments precluded these individuals from partici pating in many of the meetings and in the writing of our Position Paper 2 . Nonetheless, we wish to assure Ludmir and colleagues 1 that the entire brain tumour research and treatment community recognizes and values the importance and contribution of radiation oncology to the management of brain tumours. We very much look forward to continuing our interactions with colleagues in this discipline for the good of all patients with these terrible diseases.
